Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 51.20
Bid: 51.20
Ask: 51.40
Change: -0.20 (-0.39%)
Spread: 0.20 (0.391%)
Open: 51.50
High: 52.10
Low: 51.10
Prev. Close: 51.40
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio co Ceres finalises deal with Weichai

4 Dec 2018 17:49

RNS Number : 4464J
IP Group PLC
04 December 2018
 

FOR RELEASE ON

04 December 2018

 

IP Group plc - Portfolio company Ceres Power finalises strategic collaboration with Weichai; further £28m investment

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, is pleased to note that portfolio company Ceres Power Holdings plc ("Ceres", "Ceres Power" or "the Company") and Weichai Power ("Weichai"), one of the leading automobile and equipment manufacturing companies in China, have agreed a long-term strategic collaboration.

 

The agreement, which triggers a further £28m equity injection into Ceres Power, includes a Joint Venture Agreement with the commitment to create a fuel cell manufacturing JV in China, a License Agreement to transfer key technology to the JV and a new £9 million joint development agreement.

 

Prior to the new equity investment by Weichai, IP Group currently holds a direct undiluted beneficial stake of 21.3% in Ceres, developer of the SteelCell®, a world-leading, low cost Solid Oxide Fuel Cell technology.

 

Dr Robert Trezona, Head of Cleantech at IP Group, said: "Ceres Power continues to make excellent commercial progress, having signed agreements with Weichai and Bosch this year. The Company is also well funded having completed a significantly oversubscribed £20m fundraising in July as well as having agreed a combined £57m of new investment from Weichai and Bosch. Since IP Group's investment in Ceres in 2012, the Company has gone from strength to strength and is a great example of how we've helped to create a world-leading company based on scientific research carried out in the UK."

 

The highlights of Ceres' announcement are:

 

- A new Joint Development Agreement (JDA) worth £9m to Ceres for the continued development of a first range extender product for electric buses in China.

- A Joint Venture Agreement for Ceres and Weichai to invest in a major new fuel cell manufacturing facility in Shandong, China, following successful trials.

- A License Agreement which will result in significant staged Technology Transfer payments of up to £30m, and ongoing future royalties to Ceres.

- Weichai will invest a further £28m in Ceres through the exercise of its warrant at 164.5p per share to increase its stake in Ceres from just under 10% to 20%. This brings its total equity investment in Ceres to £48m.

 

Ceres has completed a number of collaborations this year including a strategic collaboration with Robert Bosch GmbH as well as a £9m strategic equity investment by Bosch into Ceres in August. Prior to that, Ceres signed a new partnership with Nissan to further develop fuel cell technology for EV applications which saw Ceres and The Welding Institute awarded a total of £8m UK Government funding through the Advanced Propulsion Centre for the project.

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Alan Aubrey, Chief Executive OfficerGreg Smith, Chief Financial OfficerLiz Vaughan-Adams, Communications

+44 (0) 20 7444 0050+44 (0) 20 7444 0062/+44 (0) 7979 853802

Charlotte Street Partners

Andrew Wilson

+44 (0) 7810 636995

Martha Walsh

+44 (0) 7876 245962

Tom Gillingham

+44 (0) 7741 659021

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAUGGQCPUPRGMC
Date   Source Headline
27th Jul 20217:03 amRNSPortfolio company Artios Pharma raises $153m
22nd Jul 202111:30 amRNSNotice of Results
1st Jul 20217:00 amRNSTotal Voting Rights
28th Jun 20217:30 amRNSDirector/PDMR Shareholding
18th Jun 20219:52 amRNSDirector/PDMR Shareholding
17th Jun 20217:00 amRNSPortfolio company Apollo Therapeutics raises $145m
15th Jun 20218:00 amRNSFurther re Scrip Dividend
9th Jun 202111:29 amRNSResult of AGM
9th Jun 20217:00 amRNSAGM Statement
7th Jun 20217:00 amRNSPortfolio co Iksuda completes $42m financing round
28th May 20213:36 pmRNSDirector/PDMR Shareholding
28th May 202110:00 amRNSJoint venture with China Everbright to launch fund
27th May 20217:00 amRNSPortfolio co Pulmocide completes $92m Series C
26th May 20212:44 pmRNSUpdate on AGM
20th May 202110:01 amRNSScrip Dividend Reference Price
17th May 202112:44 pmRNSAdditional fair value gain of £20m
12th May 202112:08 pmRNSHolding(s) in Company
10th May 202111:15 amRNSInvestor webinars
6th May 20216:13 pmRNSNotice of AGM, Annual Report, Scrip Dividend
6th May 20215:55 pmRNSLTIP & DBSP awards; Director/PDMR shareholding
5th May 20217:00 amRNSPortfolio company Kuur acquired by Athenex
5th May 20217:00 amRNSPortfolio company Inivata acquired by NeoGenomics
4th May 20217:00 amRNSPortfolio company Oxford Nanopore raises £195m
7th Apr 202111:27 amRNSDirector/PDMR Shareholding
31st Mar 20219:15 amRNSHolding(s) in Company
30th Mar 20217:05 amRNSOxford Nanopore announces preparing for IPO in H2
26th Mar 202112:26 pmRNSEMA positive opinion for Diurnal's Chronocort
10th Mar 20217:00 amRNSAnnual Results
4th Mar 20216:07 pmRNSHolding(s) in Company
2nd Mar 202112:03 pmRNSHolding(s) in Company
24th Feb 202110:33 amRNSNotice of Results
18th Feb 20214:31 pmRNSHolding(s) in Company
18th Feb 20218:00 amRNSHolding(s) in Company
17th Feb 20217:00 amRNSPortfolio company ApcinteX acquired by Centessa
10th Feb 20217:00 amRNSIP Group, Inc. raises $50.0m (£36.5m*) of funding
9th Feb 20213:52 pmRNSHolding(s) in Company
2nd Feb 20215:15 pmRNSHolding(s) in Company
11th Jan 20215:29 pmRNSHolding(s) in Company
6th Jan 20214:57 pmRNSPortfolio co Hinge Health completes $300m round
6th Jan 202111:34 amRNSHolding(s) in Company
6th Jan 20217:00 amRNSPortfolio co Oxbotica completes £36m funding round
4th Dec 202011:41 amRNSHolding(s) in Company
3rd Dec 20208:01 amRNSArtios and Merck in global strategic collaboration
25th Nov 20207:00 amRNSDirector Declaration
23rd Nov 20205:05 pmRNSHolding(s) in Company
21st Oct 20207:00 amRNSInvestor webinar
13th Oct 20207:00 amRNSOxford Nanopore funding round and contract win
9th Oct 20209:46 amRNSOxford Nanopore's LamPORE test gains CE-IVD mark
7th Oct 20207:00 amRNSEnterprise Therapeutics' program acquired by Roche
23rd Sep 20201:40 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.